Cite
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
MLA
Colombo, N., et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1308940779&authtype=sso&custid=ns315887.
APA
Colombo, N., Dubot, C., Lorusso, D., Caceres, M., Hasegawa, K., Shapira-Frommer, R., Tewari, K., Salman, P., Hoyos Usta, E., Yañez, E., Gümüş, M., Olivera Hurtado de Mendoza, M., Samouëlian, V., Castonguay, V., Arkhipov, A., Toker, S., Li, K., Keefe, S., Monk, B., … Monk, B. J. (2021). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Chicago
Colombo, N, C Dubot, D Lorusso, M Caceres, K Hasegawa, R Shapira-Frommer, K Tewari, et al. 2021. “Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1308940779&authtype=sso&custid=ns315887.